Synapse - Saad Usmani

Results (296)

Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach

Journal Article

Pianko, M. J.; Tiutan, T.; Derkach, A.; Flynn, J.; Salvatore, S. P.; Jaffer-Sathick, I.; Rossi, A. C.; Lahoud, O.; Hultcrantz, M.; Shah, U. A.; more...
American Journal of Hematology (2023)

Fulltext@MSK | Save

Extreme body mass index and survival in newly diagnosed multiple myeloma patients

Correspondence

Shah, U. A.; Whiting, K.; Devlin, S.; Ershler, R.; Kanapuru, B.; Lee, D. J.; Tahri, S.; Gwise, T.; Rustad, E. H.; Mailankody, S.; more...
Blood Cancer Journal (2023)

Fulltext@MSK | Save

Standardizing clinical workflow for assessing minimal residual disease by flow cytometry in multiple myeloma

Journal Article

Foureau, D. M.; Paul, B. A.; Guo, F.; Lipford, E. H.; Fesenkova, K.; Tjaden, E.; Drummond, K.; Bhutani, M.; Atrash, S.; Ndiaye, A.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

Journal Article

Usmani, S. Z.; Nahi, H.; Legiec, W.; Grosicki, S.; Vorobyev, V.; Spicka, I.; Hungria, V.; Korenkova, S.; Bahlis, N. J.; Flogegard, M.; more...
Haematologica (2022)

Fulltext@MSK | Save

CARTITUDE-1: Two-year post last patient in (LPI) results from the phase 1b/2 study of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) cell therapy, in patients with relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Usmani, S. Z.; Martin, T.; Berdeja, J. G.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A.; Munshi, N. C.; more...
Clinical Lymphoma, Myeloma and Leukemia (2022)

Fulltext@MSK | Save

Adjusted comparison of teclistamab versus physician's choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma

Meeting Abstract

Mateos, M. V.; Chari, A.; Usmani, S.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; more...
Clinical Lymphoma, Myeloma and Leukemia (2022)

Fulltext@MSK | Save

Addition of ixazomib to pomalidomide-dexamethasone improves progression-free survival for myeloma patients progressing on frontline lenalidomide: results of the randomized alliance study A061202

Meeting Abstract

Voorhees, P.; Suman, V.; Efebera, Y.; Raje, N.; Tuchman, S.; Rodriguez, C.; Santo, K.; Bova-Solem, M.; Carlisle, D.; Usmani, S.; more...
Clinical Lymphoma, Myeloma and Leukemia (2022)

Fulltext@MSK | Save

Comparative effectiveness of teclistamab versus real-world physician's choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma

Meeting Abstract

Krishnan, A.; Nooka, A.; Chari, A.; Garfall, A.; Martin, T.; Nair, S.; Lin, X.; Qi, K. Q.; Londhe, A.; Pei, L.; more...
Clinical Lymphoma, Myeloma and Leukemia (2022)

Fulltext@MSK | Save

Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)